BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) was the target of a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 58,500 shares, a decline of 44.8% from the May 15th total of 105,900 shares. Based on an average trading volume of 214,200 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.7% of the shares of the company are short sold.
BioNexus Gene Lab Stock Performance
NASDAQ BGLC traded down $0.04 on Friday, reaching $0.44. The stock had a trading volume of 131,294 shares, compared to its average volume of 323,953. The firm has a fifty day moving average of $0.57 and a two-hundred day moving average of $0.63. BioNexus Gene Lab has a 1-year low of $0.31 and a 1-year high of $17.88.
BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.02) earnings per share for the quarter. The company had revenue of $2.38 million for the quarter. BioNexus Gene Lab had a negative net margin of 27.24% and a negative return on equity of 30.74%.
Institutional Trading of BioNexus Gene Lab
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.
Read More
- Five stocks we like better than BioNexus Gene Lab
- 3 Monster Growth Stocks to Buy Now
- MarketBeat Week in Review – 6/10 – 6/14
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.